Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Tislelizumab (Tevimbra)

decorative image of the issue cover

Published April 23, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tislelizumab (Tevimbra), 100 mg/10 mL (10 mg/mL), concentrate for solution, IV infusion.
  • Indication: in combination with gemcitabine and cisplatin for the first‑line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).